Semaglutide has long been revealed to induce medullary thyroid mobile carcinoma in rodents. Though its clinical relevance to individuals is mysterious, the FDA advises to not administer this drug in Individuals with a personal or family background of medullary thyroid carcinoma. Semaglutide also poses a risk of pancreatitis and dehydration.Meaning